Evaluation of a potential regulatory role for inverted CCAAT boxes in the human topoisomerase II alpha promoter.
Several chemotherapeutic agents act via inhibition of topoisomerase (topo) II activity. Topo II levels appear to correlate with drug sensitivity in vivo. The DNA immediately 5' to the topo II alpha coding region contains five potentially regulatory inverted CCAAT boxes (ICB). Electrophoretic mobility shift assays (EMSA) using oligomers containing the wild type forms of these ICBs show specific DNA-protein binding. Mutations in these ICBs result in loss of protein binding. EMSA competition studies indicate that the four most 3' ICBs (1-4) bind to the same protein(s), while the most 5' ICB (5) binds to a different protein(s). EMSA supershift assays with antibodies to two known CCAAT binding proteins, CBF and CEB/P, indicate that ICBs 1-4 are binding to CBF, but ICB 5 is not bound by either of these proteins.
Herzog
C E
CE
Department of Clinical Investigation, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA. cherzog@notes.mdacc.tmc.edu
Zwelling
L A
LA
D000951:Antigens, Neoplasm; D001483:Base Sequence; D001665:Binding Sites / Q000235:genetics; D001667:Binding, Competitive; D004247:DNA / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism; D004250:DNA Topoisomerases, Type II / Q000235:genetics*; D004268:DNA-Binding Proteins; D004591:Electrophoresis, Polyacrylamide Gel; D018922:HL-60 Cells; D006801:Humans; D007527:Isoenzymes / Q000235:genetics*; D009154:Mutation; D011401:Promoter Regions, Genetic; D011485:Protein Binding
D000951:Antigens, Neoplasm; D004268:DNA-Binding Proteins; D007527:Isoenzymes; D004247:DNA; D004250:DNA Topoisomerases, Type II